Publicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (19)

2023

  1. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 4, pp. 787-799

2022

  1. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study

    Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 5, pp. 1106-1114

2021

  1. A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients

    Blood Cells, Molecules, and Diseases, Vol. 86

  2. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  3. Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa

    Expert Opinion on Biological Therapy, Vol. 21, Núm. 9, pp. 1165-1171

  4. Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project

    Haemophilia, Vol. 27, Núm. 6, pp. 1007-1021

2020

  1. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 9, pp. 2145-2154

2019

  1. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

    Scientific Reports, Vol. 9, Núm. 1

  2. Management of adult patients with primary immune thrombocytopenia (itp) in clinical practice: A consensus approach of the Spanish itp expert group

    Advances in Hematology, Vol. 2019

2018

  1. Role of multimeric analysis of von willebrand factor (VWF) in von willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project

    PLoS ONE, Vol. 13, Núm. 6

2017

  1. Molecular and clinical profile of von willebrand disease in Spain (PCM-EVW-ES): Comprehensive genetic analysis by next-generation sequencing of 480 patients

    Haematologica, Vol. 102, Núm. 12, pp. 2005-2014

2016

  1. Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study)

    Haemophilia, Vol. 22, Núm. 1, pp. 96-102

  2. Molecular and clinical profile of von willebrand disease in spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm

    Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 40-50

  3. Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: A European survey

    Haemophilia, Vol. 22, Núm. 1, pp. 110-120

  4. Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey

    Haemophilia, Vol. 22, Núm. 5, pp. 739-751

  5. Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors

    European Journal of Haematology, Vol. 96, Núm. 5, pp. 461-474

2012

  1. Continuous infusion in haemophilia: Current practice in Europe

    Haemophilia, Vol. 18, Núm. 5, pp. 753-759

2010

  1. Non-genetic risk factors and the development of inhibitors in haemophilia: A comprehensive review and consensus report

    Haemophilia, Vol. 16, Núm. 5, pp. 747-766

1996

  1. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects

    Annals of Hematology, Vol. 72, Núm. 5, pp. 321-326